These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
86 related articles for article (PubMed ID: 8378080)
41. The genomic landscape of the Ewing Sarcoma family of tumors reveals recurrent STAG2 mutation. Brohl AS; Solomon DA; Chang W; Wang J; Song Y; Sindiri S; Patidar R; Hurd L; Chen L; Shern JF; Liao H; Wen X; Gerard J; Kim JS; Lopez Guerrero JA; Machado I; Wai DH; Picci P; Triche T; Horvai AE; Miettinen M; Wei JS; Catchpool D; Llombart-Bosch A; Waldman T; Khan J PLoS Genet; 2014 Jul; 10(7):e1004475. PubMed ID: 25010205 [TBL] [Abstract][Full Text] [Related]
42. Dual targeting of the insulin-like growth factor and collateral pathways in cancer: combating drug resistance. Ludwig JA; Lamhamedi-Cherradi SE; Lee HY; Naing A; Benjamin R Cancers (Basel); 2011 Jul; 3(3):3029-54. PubMed ID: 24212944 [TBL] [Abstract][Full Text] [Related]
43. Variability in functional p53 reactivation by PRIMA-1(Met)/APR-246 in Ewing sarcoma. Aryee DN; Niedan S; Ban J; Schwentner R; Muehlbacher K; Kauer M; Kofler R; Kovar H Br J Cancer; 2013 Nov; 109(10):2696-704. PubMed ID: 24129240 [TBL] [Abstract][Full Text] [Related]
44. Suppression of FOXO1 is responsible for a growth regulatory repressive transcriptional sub-signature of EWS-FLI1 in Ewing sarcoma. Niedan S; Kauer M; Aryee DN; Kofler R; Schwentner R; Meier A; Pötschger U; Kontny U; Kovar H Oncogene; 2014 Jul; 33(30):3927-38. PubMed ID: 23995784 [TBL] [Abstract][Full Text] [Related]
45. miR-125b develops chemoresistance in Ewing sarcoma/primitive neuroectodermal tumor. Iida K; Fukushi J; Matsumoto Y; Oda Y; Takahashi Y; Fujiwara T; Fujiwara-Okada Y; Hatano M; Nabashima A; Kamura S; Iwamoto Y Cancer Cell Int; 2013 Mar; 13(1):21. PubMed ID: 23497288 [TBL] [Abstract][Full Text] [Related]
46. Redirecting T cells to Ewing's sarcoma family of tumors by a chimeric NKG2D receptor expressed by lentiviral transduction or mRNA transfection. Lehner M; Götz G; Proff J; Schaft N; Dörrie J; Full F; Ensser A; Muller YA; Cerwenka A; Abken H; Parolini O; Ambros PF; Kovar H; Holter W PLoS One; 2012; 7(2):e31210. PubMed ID: 22355347 [TBL] [Abstract][Full Text] [Related]
47. Molecular pathogenesis of Ewing sarcoma: new therapeutic and transcriptional targets. Lessnick SL; Ladanyi M Annu Rev Pathol; 2012; 7():145-59. PubMed ID: 21942527 [TBL] [Abstract][Full Text] [Related]
48. Review of therapeutic strategies for osteosarcoma, chondrosarcoma, and Ewing's sarcoma. Dai X; Ma W; He X; Jha RK Med Sci Monit; 2011 Aug; 17(8):RA177-190. PubMed ID: 21804475 [TBL] [Abstract][Full Text] [Related]
49. Hsa-mir-145 is the top EWS-FLI1-repressed microRNA involved in a positive feedback loop in Ewing's sarcoma. Ban J; Jug G; Mestdagh P; Schwentner R; Kauer M; Aryee DN; Schaefer KL; Nakatani F; Scotlandi K; Reiter M; Strunk D; Speleman F; Vandesompele J; Kovar H Oncogene; 2011 May; 30(18):2173-80. PubMed ID: 21217773 [TBL] [Abstract][Full Text] [Related]
50. Targeting the p53 Pathway in Ewing Sarcoma. Neilsen PM; Pishas KI; Callen DF; Thomas DM Sarcoma; 2011; 2011():746939. PubMed ID: 21197471 [TBL] [Abstract][Full Text] [Related]
52. A molecular function map of Ewing's sarcoma. Kauer M; Ban J; Kofler R; Walker B; Davis S; Meltzer P; Kovar H PLoS One; 2009; 4(4):e5415. PubMed ID: 19404404 [TBL] [Abstract][Full Text] [Related]
53. EWS-FLI1 suppresses NOTCH-activated p53 in Ewing's sarcoma. Ban J; Bennani-Baiti IM; Kauer M; Schaefer KL; Poremba C; Jug G; Schwentner R; Smrzka O; Muehlbacher K; Aryee DN; Kovar H Cancer Res; 2008 Sep; 68(17):7100-9. PubMed ID: 18757425 [TBL] [Abstract][Full Text] [Related]
54. BMI-1 promotes ewing sarcoma tumorigenicity independent of CDKN2A repression. Douglas D; Hsu JH; Hung L; Cooper A; Abdueva D; van Doorninck J; Peng G; Shimada H; Triche TJ; Lawlor ER Cancer Res; 2008 Aug; 68(16):6507-15. PubMed ID: 18701473 [TBL] [Abstract][Full Text] [Related]
55. Tissue microarrays: applications in study of p16 and p53 alterations in Ewing's cell lines. Noguera R; Machado I; Piqueras M; Lopez-Guerrero JA; Navarro S; Mayordomo E; Pellin A; Llombart-Bosch A Diagn Pathol; 2008 Jul; 3 Suppl 1(Suppl 1):S27. PubMed ID: 18673516 [TBL] [Abstract][Full Text] [Related]
56. Progress in the molecular biology of ewing tumors. Kovar H Sarcoma; 1998; 2(1):3-17. PubMed ID: 18521227 [TBL] [Abstract][Full Text] [Related]
57. Enhanced MDM2 Oncoprotein Expression in Soft Tissue Sarcoma: Several Possible Regulatory Mechanisms. Pollock RE; Lang A; El-Naggar AK; Radinsky R; Hung MC Sarcoma; 1997; 1(1):23-9. PubMed ID: 18521197 [TBL] [Abstract][Full Text] [Related]
58. Microsatellite instability in Ewing tumor is not associated with loss of mismatch repair protein expression. Alldinger I; Schaefer KL; Goedde D; Ottaviano L; Dirksen U; Ranft A; Juergens H; Gabbert HE; Knoefel WT; Poremba C J Cancer Res Clin Oncol; 2007 Oct; 133(10):749-59. PubMed ID: 17530287 [TBL] [Abstract][Full Text] [Related]
59. p53 overexpression in Ewing's sarcoma/primitive neuroectodermal tumour is an uncommon event. Mangham DC; Cannon A; Li XQ; Komiya S; Gebhardt MC; Springfield DS; Rosenberg AE; Mankin HJ Clin Mol Pathol; 1995 Apr; 48(2):M79-82. PubMed ID: 16695986 [TBL] [Abstract][Full Text] [Related]
60. A small nuclear RNA, hdm365, is the major processing product of the human mdm2 gene. Bartl S; Ban J; Weninger H; Jug G; Kovar H Nucleic Acids Res; 2003 Feb; 31(4):1136-47. PubMed ID: 12582232 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]